[go: up one dir, main page]

CY1115109T1 - Συνθεση αερολυματος για χαπ - Google Patents

Συνθεση αερολυματος για χαπ

Info

Publication number
CY1115109T1
CY1115109T1 CY20141100374T CY141100374T CY1115109T1 CY 1115109 T1 CY1115109 T1 CY 1115109T1 CY 20141100374 T CY20141100374 T CY 20141100374T CY 141100374 T CY141100374 T CY 141100374T CY 1115109 T1 CY1115109 T1 CY 1115109T1
Authority
CY
Cyprus
Prior art keywords
air conditioning
copper air
copper
copd
administration
Prior art date
Application number
CY20141100374T
Other languages
English (en)
Inventor
Sauro Bonelli
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115109(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1115109T1 publication Critical patent/CY1115109T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • B65B31/06—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzle being arranged for insertion into, and withdrawal from, the mouth of a filled container and operating in conjunction with means for sealing the container mouth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/10—Adding propellants in solid form to aerosol containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά σταθερές συνθέσεις διαλύματος αερολύματος, οι οποίες περιλαμβάνουν βρωμιούχο γλυκοπυρρόνιο για χορήγηση σε ασθενείς οι οποίοι πάσχουν από ΧΑΠ και άλλες αναπνευστικές παθήσεις.
CY20141100374T 2009-12-23 2014-05-26 Συνθεση αερολυματος για χαπ CY1115109T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015980 2009-12-23
EP10799029.3A EP2515854B1 (en) 2009-12-23 2010-12-22 Aerosol formualtion for COPD

Publications (1)

Publication Number Publication Date
CY1115109T1 true CY1115109T1 (el) 2016-12-14

Family

ID=42046446

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100374T CY1115109T1 (el) 2009-12-23 2014-05-26 Συνθεση αερολυματος για χαπ

Country Status (32)

Country Link
US (4) US20110150783A1 (el)
EP (1) EP2515854B1 (el)
JP (1) JP5800829B2 (el)
KR (1) KR101747474B1 (el)
CN (1) CN102665680B (el)
AU (2) AU2010334858A1 (el)
CA (1) CA2785317C (el)
CL (1) CL2012001668A1 (el)
CO (1) CO6551734A2 (el)
CY (1) CY1115109T1 (el)
DK (1) DK2515854T3 (el)
EA (1) EA021604B1 (el)
ES (1) ES2464520T3 (el)
GE (1) GEP20166479B (el)
HK (1) HK1174568A1 (el)
HR (1) HRP20140550T1 (el)
IL (1) IL220534A0 (el)
MA (1) MA33821B1 (el)
MX (1) MX340264B (el)
MY (1) MY156950A (el)
NZ (1) NZ600789A (el)
PE (1) PE20121467A1 (el)
PH (1) PH12012501063A1 (el)
PL (1) PL2515854T3 (el)
PT (1) PT2515854E (el)
RS (1) RS53355B (el)
SG (1) SG181870A1 (el)
SI (1) SI2515854T1 (el)
TN (1) TN2012000261A1 (el)
UA (1) UA106098C2 (el)
WO (1) WO2011076842A2 (el)
ZA (1) ZA201204613B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561052C2 (ru) * 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
CN102665679B (zh) 2009-12-23 2014-11-26 奇斯药制品公司 用于copd的联合治疗
CN102665680B (zh) * 2009-12-23 2014-07-30 奇斯药制品公司 用于copd的气雾剂制剂
ME03076B (me) * 2013-12-30 2019-01-20 Chiesi Farm Spa Stabilna pod priтiskom kompozicija aerosolnog rastvora glikopironijum bromida i kombinacije formoterola
MY182861A (en) * 2013-12-30 2021-02-05 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
MX375783B (es) 2015-12-04 2025-03-07 Mexichem Fluor Sa De Cv Composiciones farmacéuticas que comprenden un compuesto de formoterol, un corticosteroide y un componente propelente.
ES2968212T3 (es) 2016-09-19 2024-05-08 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
KR20230052903A (ko) 2020-07-31 2023-04-20 케모 리서치, 에스.엘. 흡입 투여를 위한 병용 요법
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
PE20240629A1 (es) 2020-10-09 2024-03-26 Chiesi Farm Spa Formulacion farmaceutica para inhalador presurizado de dosis medidas
KR20250016250A (ko) 2022-05-27 2025-02-03 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 약제학적 제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SG52459A1 (en) 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CZ303833B6 (cs) * 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2002234476B2 (en) * 2001-03-30 2006-04-27 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
HUE049426T2 (hu) 2002-03-01 2020-09-28 Chiesi Farm Spa Szuperfinom formoterolkészítmény
JP2006510680A (ja) 2002-12-16 2006-03-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト チオトロピウムを含有するｈｆｃ溶液調合物
DK1718336T3 (da) * 2004-02-06 2008-10-20 Meda Pharma Gmbh & Co Kg Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2008314628B2 (en) 2007-10-18 2014-03-06 Rose U Topical glycopyrrolate formulations
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102665679B (zh) * 2009-12-23 2014-11-26 奇斯药制品公司 用于copd的联合治疗
RU2561052C2 (ru) * 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
EP2515856B1 (en) * 2009-12-23 2014-04-02 Chiesi Farmaceutici S.p.A. Aerosol Formulation for COPD
CN102665680B (zh) * 2009-12-23 2014-07-30 奇斯药制品公司 用于copd的气雾剂制剂
BR112013002504A2 (pt) * 2010-08-03 2016-05-31 Chiesi Farma Spa formulação farmacêutica para administração em aerosol, inalador pressurizado dosimetrado (pmdi), formulação farmacêutica para nebulização, frasco de dose única ou múltiplas e uso de uma formulação
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
ME03076B (me) * 2013-12-30 2019-01-20 Chiesi Farm Spa Stabilna pod priтiskom kompozicija aerosolnog rastvora glikopironijum bromida i kombinacije formoterola
MY182861A (en) * 2013-12-30 2021-02-05 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Also Published As

Publication number Publication date
MX2012006879A (es) 2012-07-04
CN102665680A (zh) 2012-09-12
KR101747474B1 (ko) 2017-06-14
PE20121467A1 (es) 2012-11-07
CL2012001668A1 (es) 2012-12-07
ES2464520T3 (es) 2014-06-03
AU2016234894B2 (en) 2018-02-22
CA2785317A1 (en) 2011-06-30
US20150306026A1 (en) 2015-10-29
HK1174568A1 (en) 2013-06-14
PH12012501063A1 (en) 2013-02-04
CA2785317C (en) 2018-02-27
HRP20140550T1 (hr) 2014-07-18
JP2013515695A (ja) 2013-05-09
CO6551734A2 (es) 2012-10-31
GEP20166479B (en) 2016-05-25
MY156950A (en) 2016-04-15
JP5800829B2 (ja) 2015-10-28
EP2515854A2 (en) 2012-10-31
ZA201204613B (en) 2013-09-25
MA33821B1 (fr) 2012-12-03
US10806701B2 (en) 2020-10-20
SI2515854T1 (sl) 2014-07-31
AU2010334858A1 (en) 2012-07-12
DK2515854T3 (da) 2014-05-26
WO2011076842A3 (en) 2011-12-01
CN102665680B (zh) 2014-07-30
WO2011076842A2 (en) 2011-06-30
UA106098C2 (uk) 2014-07-25
US20230157951A1 (en) 2023-05-25
KR20120120160A (ko) 2012-11-01
RS53355B (en) 2014-10-31
TN2012000261A1 (en) 2013-12-12
PL2515854T3 (pl) 2014-08-29
EA201290374A1 (ru) 2013-01-30
BR112012015336A2 (pt) 2016-03-15
IL220534A0 (en) 2012-08-30
EA021604B1 (ru) 2015-07-30
US11590074B2 (en) 2023-02-28
MX340264B (es) 2016-07-04
US20110150783A1 (en) 2011-06-23
SG181870A1 (en) 2012-07-30
EP2515854B1 (en) 2014-03-19
US20210000738A1 (en) 2021-01-07
AU2016234894A1 (en) 2016-10-13
NZ600789A (en) 2014-09-26
PT2515854E (pt) 2014-05-27

Similar Documents

Publication Publication Date Title
CY1115109T1 (el) Συνθεση αερολυματος για χαπ
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1121360T1 (el) Αναστολεις dna-pk
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1114804T1 (el) Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις
CY1118034T1 (el) Συνθεσεις για αναπνευστικη απελευθερωση ενεργων παραγοντων και συσχετιζομενες μεθοδοι και συστηματα
EA201170227A1 (ru) Имидазолкарбоксамиды
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
BR112015029970A2 (pt) inibidores de cinase
CY1116576T1 (el) Αμιδια αμινοϊνδανιων που εχουν υψηλη μυκητοκτονο δραση και οι φυτοϋγειονομικες συνθεσεις τους
CY1115116T1 (el) Συνδυαστικη θεραπεια για χαπ
UY3723Q (es) Aerosol
CY1115030T1 (el) Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
EA201190108A1 (ru) Фармацевтическая композиция для ингаляции
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1116076T1 (el) Νεα μεθοδος για την παρασκευη σκοπινεστερων
CY1117328T1 (el) Διαδικασια για την παρασκευη πολυσιαλικου οξεος υψηλης καθαρiοτητας
EA201070689A1 (ru) Композиция для личного ухода
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
ITMI20060158U1 (it) Apparecchiatura per la somministrazione di ossigeno o di aria addizionata da ossigeno,per terapie respiratorie.
CY1119468T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη